3
Announcements
Trials
Browse
Landscape
Status
Completed
25
Unknown
6
Terminated
6
Active not recruiting
2
Withdrawn
1
Suspended
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Gastrointestinal Stromal Tumors
2
Rare Tumour
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Piebaldism
1
Interventions
blinatumomab
10
Cyclophosphamide
6
fludarabine
4
Vincristine
4
Methotrexate
4
Dexamethasone
4
Cytarabine
4
venetoclax
3
Whole-Body Irradiation
2
Thiotepa
2
Therapeutics
2
Mercaptopurine
2
Exercise
2
Busulfan
2
ruxolitinib
1
revumenib
1
ponatinib
1
pegaspargase
1
olverembatinib
1
navitoclax
1
fludarabine phosphate
1
etoposide phosphate
1
capivasertib
1
asciminib
1
Ultrasonography
1
Transplantation
1
Prednisolone
1
Melphalan
1
Levofloxacin
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Imatinib Mesylate
×
Clear all
NCT06175702
2023-12-19
LALPh2022
PETHEMA Foundation
Not yet recruiting
150 enrolled